Predicted to enable D-erythro-sphingosine kinase activity. Acts upstream of or within several processes, including cellular response to ceramide; embryonic viscerocranium morphogenesis; and heart development. Predicted to be active in cytoplasm; intracellular membrane-bounded organelle; and membrane. Is expressed in several structures, including blastodisc; heart; liver; pleuroperitoneal region; and yolk syncytial layer. Used to study metabolic dysfunction-associated steatohepatitis. Orthologous to human SPHK2 (sphingosine kinase 2).